Pisa P - Search Results

1

A phase I trial of DNA vaccination with a plasmid expressing prostate-specific antigen in patients with hormone-refractory prostate cancer.

Pavlenko M, Roos AK, Lundqvist A, Palmborg A, Miller AM, Ozenci V, Bergman B, Egevad L, Hellström M, Kiessling R, Masucci G, Wersäll P, Nilsson S, Pisa P. Pavlenko M, et al. Among authors: pisa p. Br J Cancer. 2004 Aug 16;91(4):688-94. doi: 10.1038/sj.bjc.6602019. Br J Cancer. 2004. PMID: 15280930 Free PMC article. Clinical Trial.

2

Induction of PSA-specific CTLs and anti-tumor immunity by a genetic prostate cancer vaccine.

Roos AK, Pavlenko M, Charo J, Egevad L, Pisa P. Roos AK, et al. Among authors: pisa p. Prostate. 2005 Feb 15;62(3):217-23. doi: 10.1002/pros.20135. Prostate. 2005. PMID: 15389792

3

Presence and specificity of tumor associated lymphocytes from ascites fluid in prostate cancer.

Ozenci V, Miller AM, Palmborg A, Egevad L, Jaremko GA, Kälkner KM, Pisa P. Ozenci V, et al. Among authors: pisa p. Prostate. 2005 Sep 15;65(1):20-6. doi: 10.1002/pros.20229. Prostate. 2005. PMID: 15800933

4

Immune monitoring in a phase 1 trial of a PSA DNA vaccine in patients with hormone-refractory prostate cancer.

Miller AM, Ozenci V, Kiessling R, Pisa P. Miller AM, et al. Among authors: pisa p. J Immunother. 2005 Jul-Aug;28(4):389-95. doi: 10.1097/01.cji.0000165353.19171.41. J Immunother. 2005. PMID: 16000958 Clinical Trial.

5

Tumor escape mechanisms in prostate cancer.

Miller AM, Pisa P. Miller AM, et al. Among authors: pisa p. Cancer Immunol Immunother. 2007 Jan;56(1):81-7. doi: 10.1007/s00262-005-0110-x. Epub 2005 Dec 16. Cancer Immunol Immunother. 2007. PMID: 16362411 Free PMC article. Review.

6

Mature dendritic cells are protected from Fas/CD95-mediated apoptosis by upregulation of Bcl-X(L).

Lundqvist A, Nagata T, Kiessling R, Pisa P. Lundqvist A, et al. Among authors: pisa p. Cancer Immunol Immunother. 2002 May;51(3):139-44. doi: 10.1007/s00262-002-0265-7. Epub 2002 Mar 1. Cancer Immunol Immunother. 2002. PMID: 11941452 Free PMC article.

7

Gene-modified dendritic cells for immunotherapy against cancer.

Lundqvist A, Pisa P. Lundqvist A, et al. Among authors: pisa p. Med Oncol. 2002;19(4):197-211. doi: 10.1385/MO:19:4:197. Med Oncol. 2002. PMID: 12512913 Review.

8

Allogeneic tumor-dendritic cell fusion vaccines for generation of broad prostate cancer T-cell responses.

Lundqvist A, Palmborg A, Bidla G, Whelan M, Pandha H, Pisa P. Lundqvist A, et al. Among authors: pisa p. Med Oncol. 2004;21(2):155-65. doi: 10.1385/MO:21:2:155. Med Oncol. 2004. PMID: 15299188

9

Identification of an immunodominant H-2D(b)-restricted CTL epitope of human PSA.

Pavlenko M, Leder C, Roos AK, Levitsky V, Pisa P. Pavlenko M, et al. Among authors: pisa p. Prostate. 2005 Jun 15;64(1):50-9. doi: 10.1002/pros.20221. Prostate. 2005. PMID: 15651071

10

Comparison of PSA-specific CD8+ CTL responses and antitumor immunity generated by plasmid DNA vaccines encoding PSA-HSP chimeric proteins.

Pavlenko M, Roos AK, Leder C, Hansson LO, Kiessling R, Levitskaya E, Pisa P. Pavlenko M, et al. Among authors: pisa p. Cancer Immunol Immunother. 2004 Dec;53(12):1085-92. doi: 10.1007/s00262-004-0559-z. Cancer Immunol Immunother. 2004. PMID: 15696608 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

163 results

Search Page

Filters